NFKB1 and cervical carcinoma: Thus,NF-κB pathway inhibitors are being considered as potential anticanceragents in cervical carcinoma.11–14 UPR signaling sensors provide a potential link betweenthe activation of the NF-κB pathway, which regulates the expression ofvarious proinflammatory genes and immunomodulatory molecules, and ER stress.15